The FDA has approved Rybrevant (amivantamab) in combination with chemotherapy to treat advanced, EGFR-mutant NSCLC that progressed on or after treatment with an EGFR TKI.

(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Breast cancer is the most common cancer in women in the United States.

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as adjuvant treatment for adults with hormone receptor (HR)-positive, ...

Source: Getty Images Phase 2 data support rovadicitinib as a new treatment option for patients with intermediate-2 or high-risk myelofibrosis who have not received prior JAK inhibitor treatment ...

Moderately hypofractionated nodal radiotherapy is not inferior to normofractionated radiotherapy for early breast cancer, data suggest.

Virtual palliative care has similar effects on quality of life as in-person care for patients with advanced non-small cell lung cancer.